This report is prior to PGX's last announcement of FY19 revenue upgrade to 150m. Upon the revenue upgrade, Canaccrord raised PT from 63c to 67c based on DCF valuation.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%